DIA/FDA Oligonucleotide-Based Therapeutic Conference 2015

Interact with renowned investigators and key health authorities to learn about the latest developments in oligonucleotide-based therapeutics. New for 2015—Enhanced poster session.

返回 Agendas

Keynote Address: The RNA Revolution and Its Translation to Medicine

Session Chair(s)

Robert T. Dorsam, PHD

Associate Director, Pharmacology/Toxicology, Office of Generic Drugs, CDER

FDA, United States

RNA based therapeutics and antisense technology promise a new means to treat many gene specific diseases. Therapeutic agents designed around RNA Interference that in somatic cells utilize the microRNA pathway to target mRNAs are advancing through clinical trials. Other RNA designed agents augment or suppress microRNA activity directly. More recently, direct delivery of mRNA is being developed in a variety of clinical settings. New opportunities for RNA based therapies also arise because of recent discoveries concerning long-noncoding RNAs and well as the CRISPR technology. The challenge of delivery of RNA type agents to cellular processes is common of all of these emerging therapies.

Speaker(s)

Phillip A. Sharp, PHD

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Techn, United States

Institute Professor